Ravafarma - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 58,069 | 90,690 | 123,034 | 139,622 | 159,823 | 151,537 | 174,520 | 171,001 |
| Profit before tax | 215 | -37,553 | 6,009 | -21,735 | 972 | -17,876 | -5,683 | 12,368 |
| Net profit | 215 | -37,553 | 6,009 | -21,735 | 972 | -17,876 | -5,683 | 12,368 |
| Equity | -39,813 | -77,366 | -71,357 | -93,092 | -92,120 | -109,996 | -115,679 | -103,311 |
| Liabilities | 115,869 | 167,522 | 199,913 | 215,564 | 230,350 | 227,853 | 240,959 | 227,798 |
| Non-current assets | 4,664 | 7,933 | 6,256 | 4,579 | 3,106 | 3,714 | 3,852 | 947 |
| Current assets | 71,129 | 81,322 | 121,537 | 117,181 | 132,424 | 112,125 | 119,636 | 122,298 |
| Total assets | 75,793 | 89,255 | 127,793 | 121,760 | 135,530 | 115,839 | 123,488 | 123,245 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 32,046 | 38,965 | 37,056 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +79.4% | +56.2% | +35.7% | +13.5% | +14.5% | -5.2% | +15.2% | -2.0% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 0.3% | -42.1% | 4.7% | -17.9% | 0.7% | -15.4% | -4.6% | 10.0% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | - | - | - | - | - | - | - | - |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 0.4% | -41.4% | 4.9% | -15.6% | 0.6% | -11.8% | -3.3% | 7.2% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 0.4% | -41.4% | 4.9% | -15.6% | 0.6% | -11.8% | -3.3% | 7.2% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | - | - | - | - | - | - | - |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 33,182 | 57,279 | 56,784 | 69,811 | 79,912 | 79,061 | 87,260 | 102,599 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Ravafarma - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2025-10-16 | 2025-10-19 | 64.37 |
| 2023-07-28 | 2023-08-01 | 0.13 |
| 2023-07-24 | 2023-07-25 | 0.13 |
| 2022-08-23 | 2022-08-30 | 1.86 |
| 2022-07-25 | 2022-08-01 | 1.86 |
| 2022-04-19 | 2022-04-24 | 621.87 |
| 2021-10-18 | 2021-11-03 | 119.53 |
Ravafarma - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Ravafarma, UAB (code 303077873) is a Private Limited Liability Company engaged in the wholesale of pharmaceutical and medical goods. In financial year 2025, the company generated revenue of €171.0K, slightly below 2024 revenue of €174.5K, but still above the €151.5K recorded in 2023. Profitability improved markedly over the three-year period: net loss was €17.9K in 2023, narrowed to €5.7K in 2024, and turned into a net profit of €12.4K in 2025. The latest profit margin was 7.2%. Balance sheet figures for 2025 show total assets of €123.2K, equity of -€103.3K, and liabilities of €227.8K, indicating a negative equity position despite stable asset levels. Long-term assets were minimal at €947, while short-term assets accounted for most of the balance sheet at €122.3K. Operational efficiency remained moderate, with asset turnover at 1.39x. Revenue per employee was €171.0K and profit per employee was €12.4K in 2025, supporting the view of a small but improving trading business.